Lu Si

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification

Jun Guo, Lu Si, Yan Kong et al. · Journal of Clinical Oncology · 2011 · 673 citations · Full text

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases

Zhihong Chi, Siming Li, Xinan Sheng et al. · BMC Cancer · 2011 · 395 citations · Full text

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

Felicity Newell, Yan Kong, James S. Wilmott et al. · Nature Communications · 2019 · 319 citations · Full text

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research · 2020 · 266 citations · Full text

Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

Lu Si, Yan Kong, Xiaowei Xu et al. · European Journal of Cancer · 2011 · 264 citations

Chinese Melanoma Patients, Skin Cancer, Medicine +10